Welcome to the ERACODA website
The European Renal Association COVID-19 Database is a European database collecting clinical information of patients on kidney replacement therapy with COVID-19.
The database currently (March 29, 2021) includes 4241 records on 4138 unique patients (74% dialysis patients and 26% kidney transplant recipients). Furthermore, follow-up data 3 months after COVID-19 diagnosis has been completed for 2210 patients and 110 centers have returned the ERACODA center questionnaire (80% of all active centers).
More than 220 clinicians representing approximately 137 centres from 33 countries (mostly in Europe and brodering the Mediterranean Sea) have contributed data to ERACODA.
The mission of ERACODA is to gain insight in what the COVID-19 epidemic means for patients treated with dialysis or a kidney transplantation across Europe, in the hope to improve their prognosis by intervening on modifiable risk factors.
The primary aim of ERACODA is to investigate the clinical course and outcomes (including hospital admission, intensive care admission and mortality) of patients on kidney replacement therapy with COVID-19. Such information may guide clinical treatment decisions and support triage strategies for admission to critical care units.
A secondary aim is to gain information on risk factors for mortality. Knowledge on modifiable patient and treatment characteristics associated with outcome may lead to interventions or changes in transplantation strategies that can improve prognosis.
What data are collected?
Data are collected from all outpatient and hospitalized adult patients (aged ≥18 years) with a functioning kidney allograft or on maintenance dialysis treatment who are diagnosed with COVID-19. This diagnosis needs to be based on a positive result on a real-time polymerase chain reaction (PCR) assay of nasal or pharyngeal swab specimens, and/or compatible findings on a CT scan or chest X-ray of the lungs.